The FDA granted galinpepimut-S a rare pediatric disease designation for the treatment of pediatric patients with acute ...
The FDA grants rare pediatric disease designation for serious or life-threatening diseases that affect fewer than 200,000 people in the United States when those people are primarily younger than 18 ...
The agent is currently being evaluated in a phase 1a study, and a phase 1b/2a study will continue to assess LP-184’s safety ...
Theriva Biologics (NYSE American: TOVX), ("Theriva” or the "Company”), a clinical-stage company developing therapeutics ...
Hyperammonemia Treatment MarketThe global hyperammonemia treatment market size is expected to reach a valuation of USD ...
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and ...
Arialys Therapeutics, a clinical-stage biotechnology company pioneering new precision medicines for autoimmune neuropsychiatry, today announced the appointment of Sankalp "Sam" Gokhale, M.D., as Chief ...
Theranexus has developed the first oral solution of miglustat tailored to the needs of patients with Niemann-Pick type C disease, Theranexus is preparing to register this formulation with the EMA ...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that five abstracts have been accepted for e-Poster ...
Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that Edesa management and business ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback